GO
Loading...

FDA OK's New Version of Johnson & Johnson's Risperdal

Johnson & Johnson said U.S. regulators have approved the company's long-lasting version of its blockbuster schizophrenia treatment Risperdal.

The long-lasting version, Invega, or paliperidone, is a once-daily oral drug designed to deliver risperidone, the active ingredient in both Invega and Risperdal, through a technology that allows the drug to remain in the body over a longer period of time.

Invega, considered by some the most important drug in J&J's pipeline, will be marketed in the United States by the company's Janssen LP unit.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More*

Don't Miss

U.S. Video

  • CNBC's Tyler Mathisen looks back at the week's top business and financial stories. The markets were closed for Thanksgiving, but did manage to hit new highs. Low oil prices gave consumers more money to spend for Black Friday.

  • Cyber Monday deals on Walmart's website on Dec. 2, 2013.

    CNBC's Tyler Mathisen looks ahead to what are likely to be next week's top stories. The jobs report comes out this week, as do auto sales. And the Rockefeller Center Christmas tree is lit.

  • Following last week's wild energy ride, analysts expect oil prices to continue to drop during the holiday season. CNBC's Patti Domm reports.